Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

How Good Is Xoma’s Good News?

February 4, 2017 0

XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery Congenital Hyperinsulinism Phase 2 …

Companies Targeted for Takeover Yet Can Thrive on their Own

February 2, 2017 0

It seems that the global Takeda (TKPYY) has guessed well what it should pick in order …

Incyte and Calithera Collaboration Is Fair and Lucrative for Both Firms

January 30, 2017 0

Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a Small Molecule Arginase Inhibitor …

Prohost Letter #404 Part 1

January 23, 2017 0

Prohost Letter #404 Part 1 HAPPY SPIRITUAL HOLIDAYS HAPPY NEW YEA

Welcoming Jounce Therapeutics (JNCE) as a Public Company

January 22, 2017 0

Today, Jounce Therapeutics has begun trading on the NASDAQ under the ticker symbol (JNCE). The Company, …

While You Were Sleeping

January 17, 2017 0

A few months ago, we heard news that a Belgium firm called Celyad (CYAD) has concluded …

Vertex and Merck KGaA Agreement Suits Both Firms

January 13, 2017 0

Vertex (VRTX) entered into a licensing agreement with Merck KGaA, Darmstadt, Germany for the worldwide development …

Will the FDA Approve Amgen’s Drug Parsabiv Next Month?

January 11, 2017 0

Amgen (AMGN) The Journal of the American Medical Association (JAMA) published findings from three Phase 3 …

Takeda Acquires Ariad for $5.2 Billion

January 9, 2017 0

ARIAD Pharmaceuticals’ (ARIA) stock jumped 75% today. The oncology firm entered into a definitive agreement to be …

Halozyme’s PEGPH20 Trial Results Are Worth Appreciating Not Doubting

January 6, 2017 0

Extremely important, not just exciting, were the results of Halozyme Therapeutics’s (HALO) Phase 2 randomized, multi-center …

Some More Important News that Precedes the Upcoming Prohost Letter

January 5, 2017 0

GILEAD (GILD) One analyst who aimed at bringing only the negatives about biotech has finally succeeded …

A Few News Before Posting the New Year Prohost Letter

January 3, 2017 0

Hi and Happy New Year 2017 In a couple of days, you will receive the NEW …

The FDA Manufacturing Issues. Why Portola Rallied but is Still Way Undervalued

December 26, 2016 0

MANUFACTURING ISSUES?! Why PORTOLA Stock Rallied? On Aug. 17, 2016, we learned that the FDA sent …

Misunderstanding the Bipartisan Senate Report on Drug Prices. See Also: Incyte Signs a Promising Collaborative Agreement with Merus N.V.

December 22, 2016 0

Observing the biotech sector’s stock prices post losses yesterday, Wednesday, Dec. 21 convinced us that investors …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd